Company research / NRIX

Nurix Therapeutics, Inc. (NRIX)

CIK 0001549595 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Nov 30

For the year ended 2025-11-30, Nurix Therapeutics, Inc. reported revenue of $83.98M. Revenue grew 54.0% from the prior annual period.

Key ratios (year ended 2025-11-30)

-340.2%
Operating margin
-314.9%
Net margin
-49.1%
Return on year-end equity
54.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 4 · 2026-09-02

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.